Dr. Uzzo on Potential of Adjuvant Therapy in Patients With RCC

Video

Robert G. Uzzo, MD, chair, Surgical Oncology, G. Willing "Wing" Pepper Chair in Cancer Research, senior vice-president, Physician Services, president, Fox Chase Cancer Center Medical Group, Inc., professor of Surgery, Temple University Health System, Fox Chase Cancer Center, discusses recent outcomes of adjuvant therapy as seen in clinical trials for patients with renal cell carcinoma (RCC).

Robert G. Uzzo, MD, chair, Surgical Oncology, G. Willing "Wing" Pepper Chair in Cancer Research, senior vice-president, Physician Services, president, Fox Chase Cancer Center Medical Group, Inc., professor of Surgery, Temple University Health System, Fox Chase Cancer Center, discusses recent outcomes of adjuvant therapy as seen in clinical trials for patients with renal cell carcinoma (RCC).

The field of adjuvant therapy for kidney cancer is rapidly evolving, Uzzo explains. There have been 2 decades worth of clinical trial research looking at this area, none of which have had practice-changing outcomes. Currently, for resectable high-risk patients with kidney cancer, there is an "X" percent chance for recurrence, he says, but there is no way to decrease that chance. Therefore, many trials are looking at this area to change outcomes for patients.

One recent trial in this area was the ASSURE (E2805) study, which Uzzo was a urology principal investigator on. This was a negative trial that compared sunitinib (Sutent) to sorafenib (Nexavar) to placebo in approximately 1900 patients.

Additionally, the S-TRAC trial explored sunitinib in patients with high-risk clear cell RCC. These findings showed an improvement in disease-free survival, but it was not statistically significant for overall survival.

Though there is a question on whether or not clinical trials looking at adjuvant therapy for RCC would accrue patients, the answer is clearly yes, Uzzo concludes.

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira, and Kilian Guse, PhD, the vice president of genetic medicine platforms at Pacira
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Related Content
© 2025 MJH Life Sciences

All rights reserved.